Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR-Reference-Cited by-同舟云学术

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Published:2018-09-20 Issue:12 Volume:103 Page:2079-2087
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Spencer Andrew,Lentzsch Suzanne,Weisel Katja,Avet-Loiseau Hervé,Mark Tomer M.,Spicka Ivan,Masszi Tamas,Lauri Birgitta,Levin Mark-David,Bosi Alberto,Hungria Vania,Cavo Michele,Lee Je-Jung,Nooka Ajay K.,Quach Hang,Lee Cindy,Barreto Wolney,Corradini Paolo,Min Chang-Ki,Scott Emma C.,Chanan-Khan Asher A.,Horvath Noemi,Capra Marcelo,Beksac Meral,Ovilla Roberto,Jo Jae-Cheol,Shin Ho-Jin,Sonneveld Pieter,Soong David,Casneuf Tineke,Chiu Christopher,Amin Himal,Qi Ming,Thiyagarajah Piruntha,Sasser A. Kate,Schecter Jordan M.,Mateos Maria-Victoria

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study;Annals of Hematology;2024-09-04

2. The Perspective of Romanian Patients on Continuous Therapy for Multiple Myeloma;Journal of Personalized Medicine;2024-08-28

3. Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence;British Journal of Haematology;2024-07-19

4. Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations;Diagnostics;2024-05-29

5. Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China;Cancer Medicine;2024-05